Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells

BACKGROUND: Dendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8(+) T-cell-mediated tumor immune responses. Vaccine immunogenicity could be enhanced by specific delivery of immunogenic tumor antigen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Masterman, Kelly-Anne, Haigh, Oscar L, Tullett, Kirsteen M, Leal-Rojas, Ingrid M, Walpole, Carina, Pearson, Frances E, Cebon, Jonathon, Schmidt, Christopher, O'Brien, Liam, Rosendahl, Nikita, Daraj, Ghazal, Caminschi, Irina, Gschweng, Eric H, Hollis, Roger P, Kohn, Donald B, Lahoud, Mireille H, Radford, Kristen J
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7394304/
https://ncbi.nlm.nih.gov/pubmed/32737142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000691
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados